Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems
- 366 Downloads
Expression of androgen receptor (AR) splice variants in metastatic castration resistant prostate cancer (mCRPC) patients is thought to effectuate resistance to novel hormone therapies (NHT) [1, 2]. Indeed, Antonarakis et al. demonstrated that mCRPC patients expressing AR-V7 in circulating tumor cells (CTCs) did not respond to NHT, i.e. abiraterone or enzalutamide, whereas response to taxane based chemotherapy was not affected [3, 4]. Further studies reinforced the potential of AR-V7 as a treatment selection biomarker [5, 6, 7].
Most approaches to detect AR-V7 in patients’ CTCs need to enrich these cells from the billions of blood cells surrounding CTCs in the blood stream. These techniques need to be applied within a few hours after blood draw to isolate intact RNA for downstream applications. Thus, shipping and subsequent processing of blood samples for global clinical studies are cost intensive and hard to manage within clinical routine. Therefore, an improvement of the...
KeywordsAbiraterone Enzalutamide Abiraterone Acetate CRPC Patient Metastatic Castration Resistant Prostate Cancer
- 16.Kim SH, Park WS, Lee SJ, et al (2015) The quantified level of circulating prostate stem cell antigen mRNA relative to GAPDH level is a clinically significant indictor for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy. Biomed Res Int 2015:292454. doi: 10.1155/2015/292454 PubMedPubMedCentralGoogle Scholar